The incidence, mortality, and risk factors of prostate cancer in Asian men

Byung Ha Chung; Shigeo Horie; Edmund Chiong

doi:10.1016/j.prnil.2018.11.001

The incidence, mortality, and risk factors of prostate cancer in Asian men

Byung Ha Chung, Shigeo Horie, Edmund Chiong

Department of Urology

Research output: Contribution to journal › Review article › peer-review

60 Citations (Scopus)

Abstract

The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Prostate International
Volume	7
Issue number	1
DOIs	https://doi.org/10.1016/j.prnil.2018.11.001
Publication status	Published - 2019 Mar

Bibliographical note

Funding Information:
Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr Chung would like to report the following: honoraria and travel expenses from Astellas (Korea), Ipsen (Korea), JW Pharma (Korea), Takeda (Korea) and Janssen (USA); consultation/advisory from Janssen (Korea), Handok (Korea), Astellas (Korea), Ipsen (Korea), Amgen (Korea), Takeda (Korea) and JW Pharma (Korea); researching funding from Janssen (USA), Bayer (Germany), Pfizer (USA), Astra Zeneca (UK), Roche (Switzerland), Myovant Sciences GmbH (Australia).

Funding Information:
Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr. Chung has nothing to disclose.

Publisher Copyright:
© 2019

All Science Journal Classification (ASJC) codes

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.prnil.2018.11.001

Cite this

@article{552529fe17b94a898d2de9bbd60d58d8,

title = "The incidence, mortality, and risk factors of prostate cancer in Asian men",

abstract = "The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.",

author = "{Ha Chung}, Byung and Shigeo Horie and Edmund Chiong",

note = "Funding Information: Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr Chung would like to report the following: honoraria and travel expenses from Astellas (Korea), Ipsen (Korea), JW Pharma (Korea), Takeda (Korea) and Janssen (USA); consultation/advisory from Janssen (Korea), Handok (Korea), Astellas (Korea), Ipsen (Korea), Amgen (Korea), Takeda (Korea) and JW Pharma (Korea); researching funding from Janssen (USA), Bayer (Germany), Pfizer (USA), Astra Zeneca (UK), Roche (Switzerland), Myovant Sciences GmbH (Australia). Funding Information: Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr. Chung has nothing to disclose. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = mar,

doi = "10.1016/j.prnil.2018.11.001",

language = "English",

volume = "7",

pages = "1--8",

journal = "Prostate International",

issn = "2287-8882",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - The incidence, mortality, and risk factors of prostate cancer in Asian men

AU - Ha Chung, Byung

AU - Horie, Shigeo

AU - Chiong, Edmund

N1 - Funding Information: Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr Chung would like to report the following: honoraria and travel expenses from Astellas (Korea), Ipsen (Korea), JW Pharma (Korea), Takeda (Korea) and Janssen (USA); consultation/advisory from Janssen (Korea), Handok (Korea), Astellas (Korea), Ipsen (Korea), Amgen (Korea), Takeda (Korea) and JW Pharma (Korea); researching funding from Janssen (USA), Bayer (Germany), Pfizer (USA), Astra Zeneca (UK), Roche (Switzerland), Myovant Sciences GmbH (Australia). Funding Information: Dr. Horie reports grants and personal fees from Takeda, Sanofi, and Astellas and personal fees from Astrazeneca and SanofiJanssen, outside the submitted work. Dr. Chiong reports nonfinancial support from Takeda Pharmaceutical Company Ltd, during the conduct of the study. Dr. Chung has nothing to disclose. Publisher Copyright: © 2019

PY - 2019/3

Y1 - 2019/3

N2 - The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.

AB - The objective of this review was to describe the epidemiology and risk factors of prostate cancer (PCa) in Asian populations. English language publications published over the last 10 years covering studies on the incidence, mortality, and risk factors of PCa in Asia were reviewed. The incidence of PCa in Asia is rising but is still significantly lower than that in Western countries. Studies in Asia indicated that the consumption of red meat, fat, dairy, and eggs was associated with a higher risk for PCa. Age and family history were also found to be risk factors. The emergence of genetic data indicates that different genetic backgrounds between Asian and Western populations play a role in the observed differences in PCa incidence. The lower incidence of PCa in Asian men than in Western men may in part be due to a lack of systematic prostate-specific antigen screening, but environmental and genetic factors also play a role.

UR - http://www.scopus.com/inward/record.url?scp=85062418728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062418728&partnerID=8YFLogxK

U2 - 10.1016/j.prnil.2018.11.001

DO - 10.1016/j.prnil.2018.11.001

M3 - Review article

AN - SCOPUS:85062418728

SN - 2287-8882

VL - 7

SP - 1

EP - 8

JO - Prostate International

JF - Prostate International

IS - 1

ER -

The incidence, mortality, and risk factors of prostate cancer in Asian men

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this